Stereotaxis Launches Odyssey Cinema™ Studio as the Industry’s First Clinical Procedure Online Broadcast Platform

Stereotaxis also announced an agreement with the North American Center for Continuing Medical Education, LLC (NACCME) to accelerate the advancement of cardiovascular care worldwide as their exclusive live broadcast platform for delivering medical education via the Odyssey Cinema Studio.  NACCME, an accredited medical education provider, is introducing the Cardiovascular Learning Network® (CVLN) to enhance its ability to bring innovative, high-quality education to its network of more than 26,000 cardiovascular medical professionals.  Stereotaxis and NACCME/CVLN will jointly broadcast educationally relevant cases to the worldwide cardiovascular community, supporting collaboration and best practice sharing to improve patient care.    These cases will also include the ability for participants to interact with world renowned professionals through on-line question and answer capabilities.

"We expect that Internet-enabled procedure broadcasts will transform medical education as participants can remotely view procedures in high definition, often related to the latest medical treatment techniques used by world-class physicians," said Michael P. Kaminski, Stereotaxis President and CEO.  "We are very excited that Odyssey Cinema Studio has been chosen as the exclusive live online broadcasting platform by NACCME and its new Cardiovascular Learning Network® to jointly provide far-reaching medical education from Odyssey-equipped labs around the world."

About Stereotaxis             www.stereotaxis.com         www.odysseyexperience.com

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation and reduced x-ray exposure.

Stereotaxis' Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. The Odyssey Cinema™ Studio then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed.  The Odyssey™ solution then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.

The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

SOURCE Stereotaxis, Inc.